tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Revive Therapeutics Advances Nerve Agent Countermeasure Study with Canadian Defence
PremiumCompany AnnouncementsRevive Therapeutics Advances Nerve Agent Countermeasure Study with Canadian Defence
3M ago
Revive Therapeutics nears completion of nerve agent countermeasure study
Premium
The Fly
Revive Therapeutics nears completion of nerve agent countermeasure study
3M ago
Revive Therapeutics Advances Next-Gen Bucillamine for Critical Medical Needs
Premium
Company Announcements
Revive Therapeutics Advances Next-Gen Bucillamine for Critical Medical Needs
4M ago
Revive Therapeutics to investigate Bucillamine’s potential in cancer treatment
PremiumThe FlyRevive Therapeutics to investigate Bucillamine’s potential in cancer treatment
6M ago
Revive Therapeutics Expands Pipeline with Molecular Hydrogen Acquisition
Premium
Company Announcements
Revive Therapeutics Expands Pipeline with Molecular Hydrogen Acquisition
6M ago
Revive enters asset purchase agreement for molecular hydrogen program
Premium
The Fly
Revive enters asset purchase agreement for molecular hydrogen program
6M ago
Revive Therapeutics Advances Bucillamine Research for Nerve Agents and Long COVID
PremiumCompany AnnouncementsRevive Therapeutics Advances Bucillamine Research for Nerve Agents and Long COVID
8M ago
Revive Therapeutics Advances Research on Bucillamine for Nerve Agent Exposure
Premium
Company Announcements
Revive Therapeutics Advances Research on Bucillamine for Nerve Agent Exposure
9M ago
Revive Therapeutics provides update on research study of bucillamine
Premium
The Fly
Revive Therapeutics provides update on research study of bucillamine
9M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100